Dear Colleagues,
Immunotherapy is recognized as a major scientific advance that has revolutionized cancer therapy over the last few years. However, there is an urgent need to identify novel biomarkers that predict the complex responses to immune checkpoint inhibitors. This could further improve treatment responses and prolong the survival of cancer patients. Biomarkers are biological/pathological molecules found in patient blood, tumor cells and tissues. They can be present at the genomic, cellular or soluble level, and be in the form of host genomic factors, serum proteins, and nucleic acids (DNA or RNA molecules) present within tumor cells or their microenvironment. Ideal biomarkers will help healthcare professionals achieve optimal treatment goals and bring clinical benefits to patients. Over the past decades, multiple tumor biomarkers have been validated and are now widely used in clinics with proven effectiveness. However, there is still a need to improve the efficacy of cancer treatments by identifying more reliable biomarkers.
The development of high-throughput sequencing technologies in proteomics and genomics has allowed single and multifactorial synergistic biomarkers to be investigated for clinical purposes using a variety of biomarker strategies. For example, mass spectrometry has improved the diagnosis of hybrid tumors and bulk, while single cell sequencing has improved our current understanding of specific tumor cell markers used for early diagnosis. The identification of multiple immune-checkpoint markers that are critical to the development of therapeutic targets for precise immune-oncology should also have a profound impact in the field of personalized medicine.
The aim of this Special Issue is to bring together original research and review articles that focus on the identification of novel predictive biomarkers for cancer diagnosis and prognosis, with an emphasis on immunotherapy.
Potential topics include but are not limited to the following:
- Biomarkers for predicting tumor recurrence and metastasis
- Biomarkers for the identification of tumor-associated cell types
- Biomarkers for tumor diagnosis and as immunotherapy targets
- Use of biomarkers for the assessment of tumor prognosis
- Liquid biopsy biomarkers such as circulating tumor DNA or peripheral blood cell biomarkers
- New methodologies including algorithms used for the characterization of tumor biomarkers
- Biomarkers associated with the tumor immune microenvironment phenotype
- Tumor genome and neoantigen-related biomarkers
- Spatial-temporal changes and regulatory mechanisms involved with biomarkers
Prof. Fu Wang
Guest Editor
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.
- Open Access Original ResearchTumor Cell-Derived Complement Component C1r Acts as a Prognostic Biomarker and Promotes Esophageal Squamous Cell Carcinoma ProgressionMaolin Tang, Shisheng Zhao, Ling Ren, Qianqian Li, ... Weimin HuFront. Biosci. (Landmark Ed) 2024, 29(4), 138; https://doi.org/10.31083/j.fbl2904138(This article belongs to the Special Issue Targeting of Multiple Predictive Biomarkers for Checkpoint Immunotherapy)22Downloads96Views
- Open Access Original ResearchThe Role of CD8A in the Immune Microenvironment of Breast CancerJian Chu, Shan Tang, Tangya Li, Huiwen FanFront. Biosci. (Landmark Ed) 2024, 29(2), 73; https://doi.org/10.31083/j.fbl2902073(This article belongs to the Special Issue Targeting of Multiple Predictive Biomarkers for Checkpoint Immunotherapy)20Downloads81Views
- Open Access Original ResearchBioinformatics Analysis Identifies PLA2G7 as a Key Antigen-Presenting Prognostic Related Gene Promoting Hepatocellular Carcinoma through the STAT1/PD-L1 AxisSihang Guo, Qinhe YangFront. Biosci. (Landmark Ed) 2024, 29(1), 39; https://doi.org/10.31083/j.fbl2901039(This article belongs to the Special Issue Targeting of Multiple Predictive Biomarkers for Checkpoint Immunotherapy)34Downloads168Views
- Open Access Original ResearchN6-Methyladenosine Regulator-Mediated Methylation Modification Patterns with Distinct Prognosis, Oxidative Stress, and Tumor Microenvironment in Renal Cell CarcinomaChunyang Li, Maoshu Zhu, Chuane Gao, Fuhua Lu, ... Weimin ZhongFront. Biosci. (Landmark Ed) 2024, 29(1), 33; https://doi.org/10.31083/j.fbl2901033(This article belongs to the Special Issue Targeting of Multiple Predictive Biomarkers for Checkpoint Immunotherapy)19Downloads105Views
- Open Access Original ResearchHigh MEIS3 Expression Indicates a Poor Prognosis for Patients with Stage II/III Colorectal CancerJian Ma, Haitao Li, Qianqian Gao, Weixing Zhang, ... Ziyan LiFront. Biosci. (Landmark Ed) 2023, 28(12), 338; https://doi.org/10.31083/j.fbl2812338(This article belongs to the Special Issue Targeting of Multiple Predictive Biomarkers for Checkpoint Immunotherapy)35Downloads165Views
- Open Access Original ResearchMaintenance of the Expression of c-FLIPL by Hsp70 to Resist Licochalcone A-Induced Anti-Colorectal Cancer Effect through ERK-Mediated Autophagy InductionTianpeng Li, Ting Li, Hongbin Zhang, Chunyan Liu, ... Wei ChenFront. Biosci. (Landmark Ed) 2023, 28(12), 325; https://doi.org/10.31083/j.fbl2812325(This article belongs to the Special Issue Targeting of Multiple Predictive Biomarkers for Checkpoint Immunotherapy)24Downloads130Views
- Open Access Original ResearchSilencing of CPNE1-TRAF2 Axis Restrains the Development of Pancreatic CancerYelin Song, Baolian Song, Zhichao Yu, Andong Li, ... Zuowei LiFront. Biosci. (Landmark Ed) 2023, 28(11), 316; https://doi.org/10.31083/j.fbl2811316(This article belongs to the Special Issue Targeting of Multiple Predictive Biomarkers for Checkpoint Immunotherapy)20Downloads149Views
- Open Access Original ResearchUnveiling Circular RNA-Mediated Regulatory Mechanisms in Necroptosis in Premature Ovarian FailureXin Jin, Wenjun Chen, Jiaxi Wang, Xianli Xu, ... Xuehua FengFront. Biosci. (Landmark Ed) 2023, 28(11), 314; https://doi.org/10.31083/j.fbl2811314(This article belongs to the Special Issue Targeting of Multiple Predictive Biomarkers for Checkpoint Immunotherapy)45Downloads162Views
- Open Access Original ResearchPrognostic and Immune Infiltration Signatures of GIMAP Family Genes in Clear Cell Renal Cell CarcinomaMengjiao Zhang, Xu Zhang, Jing Hou, Xuemei Liang, Ming ZhangFront. Biosci. (Landmark Ed) 2023, 28(11), 308; https://doi.org/10.31083/j.fbl2811308(This article belongs to the Special Issue Targeting of Multiple Predictive Biomarkers for Checkpoint Immunotherapy)20Downloads133Views
- Open Access Original ResearchDevelopment and Validation of a Prognosis-Prediction Signature for Patients with Lung Adenocarcinoma Based on 11 Telomere-Related GenesJia Liu, Sha Sha, Jian Wang, Xiaowei Gu, ... Xu LuFront. Biosci. (Landmark Ed) 2023, 28(10), 254; https://doi.org/10.31083/j.fbl2810254(This article belongs to the Special Issue Targeting of Multiple Predictive Biomarkers for Checkpoint Immunotherapy)44Downloads214Views
- Open Access Original ResearchConstruction and Validation of a Prognostic Model of Metabolism-Related Genes Driven by Somatic Mutation in Bladder CancerLiang Wei, Lina Ji, Shuaihong Han, Mingquan Xu, Xiaofeng YangFront. Biosci. (Landmark Ed) 2023, 28(10), 242; https://doi.org/10.31083/j.fbl2810242(This article belongs to the Special Issue Targeting of Multiple Predictive Biomarkers for Checkpoint Immunotherapy)36Downloads177Views
- Open Access Original ResearchCharacterization of DNA Damage Repair Related Signature and Molecular Feature in Low-Grade Gliomas to Aid Chemotherapy and Drug DiscoveryXin Yin, Min Li, Zheng HeFront. Biosci. (Landmark Ed) 2023, 28(10), 234; https://doi.org/10.31083/j.fbl2810234(This article belongs to the Special Issue Targeting of Multiple Predictive Biomarkers for Checkpoint Immunotherapy)29Downloads160Views
- Open Access Original ResearchSUMOylation of SMAD4 by PIAS1 in Conjunction with Vimentin Upregulation Promotes Migration Potential in Non-Small Cell Lung CancerChunli Wu, Xiaoxiao Zhu, Qi Dai, Zanbo Chu, ... Zhaoxing DongFront. Biosci. (Landmark Ed) 2023, 28(8), 192; https://doi.org/10.31083/j.fbl2808192(This article belongs to the Special Issue Targeting of Multiple Predictive Biomarkers for Checkpoint Immunotherapy)95Downloads306Views